Faienza Maria F, Chiarito Mariangela, Baldinotti Fulvia, Canale Domenico, Savino Carmela, Paradies Guglielmo, Corica Domenico, Romeo Carmelo, Tyutyusheva Nina, Caligo Maria A, Wasniewska Malgorzata G, Bertelloni Silvano
Sex Dev. 2019;13(5-6):258-263. doi: 10.1159/000507411. Epub 2020 May 6.
NR5A1 (nuclear receptor subfamily 5 group A member 1) is a transcriptional regulator of adrenal and gonadal development and function. Heterozygous and homozygous NR5A1 mutations have been described in people with 46,XY disorders of sex development (DSD). The clinical, endocrine, and genetic features of four 46,XY subjects with NR5A1 genetic variants (2 sisters, 2 boys) from 3 unrelated families are reported. All subjects presented with hypergonadotropic hypogonadism and abnormal pubertal progression. Markers of Sertoli cell function were more affected than those of Leydig cell function. Genetic investigation demonstrated the presence of different heterozygous NR5A1 genetic variants. In the boys, pathogenetic NR5A1 gene variants were found that had been previously reported. The 2 sisters carried a new genetic variant in exon 4, and in silico analysis and ACMG classification indicated its pathogenicity. The data confirmed that NR5A1 gene mutations may present with variable genital phenotypes. Anyway, reproductive function was always impaired. Any clinical or endocrine data seem to be unable to differentiate these patients from other 46,XY DSD cases, suggesting that molecular analysis must be warranted. In subjects with NR5A1 mutations, different decisions in sex assignment may permit satisfying somatic and psychological outcome, but any option requires hormonal substitutive therapy from adolescence onward.
NR5A1(核受体亚家族5组A成员1)是肾上腺和性腺发育及功能的转录调节因子。在46,XY性发育障碍(DSD)患者中已发现杂合子和纯合子NR5A1突变。本文报道了来自3个无关家庭的4名携带NR5A1基因变异的46,XY受试者(2名姐妹,2名男孩)的临床、内分泌和遗传特征。所有受试者均表现为高促性腺激素性性腺功能减退和青春期发育异常。支持细胞功能标志物比间质细胞功能标志物受影响更大。基因研究表明存在不同的杂合子NR5A1基因变异。在男孩中,发现了先前报道过的致病性NR5A1基因变异。这2名姐妹在外显子4中携带一种新的基因变异,计算机分析和ACMG分类表明其具有致病性。数据证实NR5A1基因突变可能表现出不同的生殖器表型。无论如何,生殖功能总是受损。任何临床或内分泌数据似乎都无法将这些患者与其他46,XY DSD病例区分开来,这表明必须进行分子分析。在携带NR5A1突变的受试者中,不同的性别指定决策可能会带来令人满意的躯体和心理结果,但任何选择都需要从青春期开始进行激素替代治疗。